Hypothalamic sites of action for testosterone, dihydrotestosterone, and estrogen in the regulation of luteinizing hormone secretion in male sheep.
Testosterone (T) inhibits LH secretion partly by acting at unknown sites within the brain to inhibit GnRH secretion. We tested the hypothesis that the preoptic area (POA) and arcuate-ventromedial region (ARC/VMR), areas rich in androgen and estrogen (E) receptors, are neural sites at which T and the T metabolites, dihydrotestosterone (DHT) and estrogen (E), act to suppress LH secretion. Bilateral guide cannulae were surgically implanted into either the POA or ARC/VMR of castrated male sheep. Experiments were conducted under a long day photoperiod to maximize the inhibitory effect of the steroids. In Exp 1, all sheep (n = 6/site) sequentially received bilateral implants of cholesterol (CHOL), T, or E at each site. Jugular blood samples were taken at 10-min intervals for 4 h both immediately before implant insertion and 5 days later. In Exp 2, all sheep (n = 6/site) sequentially received bilateral implants of CHOL, DHT, or E at each site according to a latin square design. Blood samples were taken before and 7 days after implant insertion. In Exp 3, which followed the same design as Exp 2, implants of E, T, or DHT were placed only in the ARC/VMR. In the final experiment, the effects of T and CHOL implants in the ARC/VMR were compared. Neither T, DHT, nor CHOL implants at either site affected LH secretion. In contrast, E treatment in the ARC/VMR suppressed mean plasma LH levels (P < 0.01), primarily due to an increase in interpulse interval (P < 0.01). Estrogen implants in the POA caused a small, but nonsignificant (P > 0.05), decrease in mean LH levels in the first experiment and an increase in LH interpulse interval (P < 0.05) in the second experiment. These results suggest that the ARC/VMR and possibly the POA are sites at which E acts to reduce GnRH secretion in male sheep.
Scott
C J
CJ
Department of Veterinary Biosciences, University of Illinois, Urbana 61801, USA.
Kuehl
D E
DE
Ferreira
S A
SA
Jackson
G L
GL
D000818:Animals; D001111:Arcuate Nucleus of Hypothalamus / Q000187:drug effects / Q000502:physiology; D002784:Cholesterol / Q000008:administration & dosage / Q000494:pharmacology; D004058:Diffusion; D013196:Dihydrotestosterone / Q000008:administration & dosage / Q000494:pharmacology*; D004343:Drug Implants; D004967:Estrogens / Q000008:administration & dosage / Q000494:pharmacology*; D005246:Feedback; D007031:Hypothalamus / Q000187:drug effects* / Q000502:physiology; D007033:Hypothalamus, Middle / Q000187:drug effects / Q000502:physiology; D007986:Luteinizing Hormone / Q000378:metabolism*; D008297:Male; D011301:Preoptic Area / Q000187:drug effects / Q000502:physiology; D012756:Sheep / Q000502:physiology*; D013739:Testosterone / Q000008:administration & dosage / Q000494:pharmacology*
D004343:Drug Implants; D004967:Estrogens; D013196:Dihydrotestosterone; D013739:Testosterone; D007986:Luteinizing Hormone; D002784:Cholesterol